TEVA Q4 2021 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$37B

Q4 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.1B-7.9% YoY

Gross Profit

$2.0B50.0% margin

Operating Income

$78M1.9% margin

Net Income

-$159M-3.9% margin

EPS (Diluted)

$-0.14

QoQ Revenue Growth

+5.5%

Cash Flow

Operating Cash Flow

$456M

Free Cash Flow

$303M

Stock-Based Comp.

$33M

Balance Sheet

Total Assets

$47.7B

Total Liabilities

$36.4B

Stockholders' Equity

$10.3B

Cash & Equivalents

$2.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.1B	$4.5B	-7.9%
Gross Profit	$2.0B	$2.0B	+0.1%
Operating Income	$78M	$406M	-80.8%
Net Income	-$159M	$150M	-206.0%

Revenue Segments

Product

$3.6B87%

Distribution Service

$374M9%

Product and Service, Other

$112M3%

License

$54M1%

Geographic Segments

North America Segment

$2.0B53%

Europe Segment

$1.3B34%

International Markets

$488M13%